{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Stable disease is defined as having \\<25% increase in serum IgM levels and \\<25% reduction in serum IgM levels","groups":[{"description":"ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles\n\nABT199: Oral BCL-2 antagonist","id":"OG000","title":"ABT199"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 participant was censored from the response analysis after it was determined that he had IgM Myeloma rather than Waldenstrom's macroglobulinemia.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With Stable Disease","type":"SECONDARY","unitOfMeasure":"Participants"}